Kolocouri Filomila, Dotsikas Yannis, Apostolou Constantinos, Kousoulos Constantinos, Soumelas Georgios-Stefanos, Loukas Yannis L
University of Athens, Division of Pharmaceutical Chemistry, Department of Pharmacy, Panepistimioupoli Zografou GR-157 71, Athens, Greece.
J AOAC Int. 2011 May-Jun;94(3):758-64.
An HPLC/MS/MS method characterized by complete automation and high throughput was developed for the determination of cilazapril and its active metabolite cilazaprilat in human plasma. All sample preparation and analysis steps were performed by using 2.2 mL 96 deep-well plates, while robotic liquid handling workstations were utilized for all liquid transfer steps, including liquid-liquid extraction. The whole procedure was very fast compared to a manual procedure with vials and no automation. The method also had a very short chromatographic run time of 1.5 min. Sample analysis was performed by RP-HPLC/MS/MS with positive electrospray ionization using multiple reaction monitoring. The calibration curve was linear in the range of 0.500-300 and 0.250-150 ng/mL for cilazapril and cilazaprilat, respectively. The proposed method was fully validated and proved to be selective, accurate, precise, reproducible, and suitable for the determination of cilazapril and cilazaprilat in human plasma. Therefore, it was applied to a bioequivalence study after per os administration of 2.5 mg tablet formulations of cilazapril.
建立了一种具有完全自动化和高通量特点的HPLC/MS/MS方法,用于测定人血浆中西拉普利及其活性代谢物西拉普利拉。所有样品制备和分析步骤均使用2.2 mL 96孔深孔板进行,同时使用自动液体处理工作站进行所有液体转移步骤,包括液-液萃取。与使用小瓶且无自动化的手动操作程序相比,整个过程非常快速。该方法的色谱运行时间也非常短,仅为1.5分钟。采用正电喷雾电离和多反应监测的RP-HPLC/MS/MS进行样品分析。西拉普利和西拉普利拉的校准曲线分别在0.500 - 300和0.250 - 150 ng/mL范围内呈线性。所提出的方法经过充分验证,证明具有选择性、准确性、精密度、可重复性,适用于测定人血浆中的西拉普利和西拉普利拉。因此,该方法应用于口服2.5 mg西拉普利片剂制剂后的生物等效性研究。